{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:18:09Z","timestamp":1793117889859,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10067-016-3474-8","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T03:40:47Z","timestamp":1478749247000},"page":"649-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study"],"prefix":"10.1007","volume":"36","author":[{"given":"Tatsuo","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"3474_CR1","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577\u2013580","journal-title":"J Rheumatol"},{"key":"3474_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51:321\u2013325","journal-title":"Arthritis Rheum"},{"key":"3474_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","volume":"12","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12:61\u201365","journal-title":"J Clin Rheumatol"},{"key":"3474_CR4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24:691\u2013697","journal-title":"Hypertens Res"},{"key":"3474_CR5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407\u20132413","journal-title":"J Am Soc Nephrol"},{"key":"3474_CR6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19:1204\u20131211","journal-title":"J Am Soc Nephrol"},{"key":"3474_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51\u201359","journal-title":"Am J Kidney Dis"},{"key":"3474_CR8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rinc\u00f3n A, Arroyo D, Lu\u00f1o J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388\u20131393","journal-title":"Clin J Am Soc Nephrol"},{"key":"3474_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacrist\u00e1n JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337\u2013343","journal-title":"Ann Pharmacother"},{"key":"3474_CR10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","volume":"26","author":"BT Emmerson","year":"1987","unstructured":"Emmerson BT, Gordon RB, Cross M, Thomson DB (1987) Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 26:445\u2013449","journal-title":"Br J Rheumatol"},{"key":"3474_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"key":"3474_CR12","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1073\/pnas.0400973101","volume":"101","author":"K Okamoto","year":"2004","unstructured":"Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T (2004) The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 101:7931\u20137936","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3474_CR13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.110.174540","volume":"336","author":"K Matsumoto","year":"2011","unstructured":"Matsumoto K, Okamoto K, Ashizawa N, Nishino T (2011) FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther 336:95\u2013103","journal-title":"J Pharmacol Exp Ther"},{"key":"3474_CR14","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.bmcl.2009.08.091","volume":"19","author":"T Sato","year":"2009","unstructured":"Sato T, Ashizawa N, Matsumoto K, Iwanaga T, Nakamura H, Inoue T, Nagata O (2009) Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051\u2014a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett 19:6225\u20136229","journal-title":"Bioorg Med Chem Lett"},{"key":"3474_CR15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S (2014) Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18:876\u2013884","journal-title":"Clin Exp Nephrol"},{"key":"3474_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","volume":"431","author":"H Yamanaka","year":"1998","unstructured":"Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, Kamatani N (1998) Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 431:13\u201318","journal-title":"Adv Exp Med Biol"},{"key":"3474_CR17","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132246","journal-title":"N Engl J Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3474-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:14:48Z","timestamp":1498360488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3474-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}